Asset profile
Fampridine · Ampyra / Fampyra
Small molecule
Evidence outlook
Approved: Multiple Sclerosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
44 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 44 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Fampridine (Ampyra / Fampyra): this drug | Approved | Small molecule | Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family), Potassium Channel Blocker | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | ||
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Cladribine (MAVENCLAD®) | Approved | Small molecule | Adenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytes | ||
| Copaxone | Approved | Peptide | Myelin basic protein-mimetic immunomodulation | ||
| Dimethyl Fumarate (Tecfidera) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Diroximel Fumarate (Vumerity) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| DRF | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Fingolimod (Gilenya) | Approved | Small molecule | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | ||
| Interferon Beta-1a (Avonex) | Approved | Biologic (subtype unspecified) | Type I Interferon receptor (IFNAR) | ||
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Interferon-Beta1 | Approved | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Mayzent | Approved | Small molecule | S1P receptor | ||
| Natalizumab (Tysabri) | Approved | Monoclonal antibody | α4 integrin | ||
| Ocrelizumab | Approved | Monoclonal antibody | CD20 |
…and 29 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (6)
May 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
What to watch
September 2027 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
2030 (1)
July 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.